^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    tinengotinib (TT-00420)

    i
    Other names: TT-00420, TT 00420, TT00420
    Company:
    TransThera Biosci
    Drug class:
    Multi-tyrosine kinase inhibitor
    Related drugs:
    Apply
    Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma (FIRST-308) (NCT05948475)
    Phase 3
    TransThera Sciences (Nanjing), Inc.
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    12/20/2023
    Primary completion :
    05/01/2026
    Completion :
    08/01/2026
    FGFR2
    |
    FGFR2 fusion
    |
    5-fluorouracil • irinotecan • tinengotinib (TT-00420)
    Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma (NCT04919642)
    Phase 2
    TransThera Sciences (Nanjing), Inc.
    Completed
    Last update posted :
    04/26/2024
    Initiation :
    12/07/2021
    Primary completion :
    02/28/2024
    Completion :
    02/28/2024
    FGFR2 • FGFR
    |
    FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR1 mutation • FGFR1 fusion • FGFR wild-type
    |
    tinengotinib (TT-00420)
    Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors (NCT04742959)
    Phase 1/2
    TransThera Sciences (Nanjing), Inc.
    Completed
    Last update posted :
    04/26/2024
    Initiation :
    03/14/2021
    Primary completion :
    02/20/2024
    Completion :
    02/20/2024
    FGFR
    |
    albumin-bound paclitaxel • tinengotinib (TT-00420)
    Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer (NCT03654547)
    Phase 1
    TransThera Sciences (Nanjing), Inc.
    Active, not recruiting
    Last update posted :
    01/03/2024
    Initiation :
    01/08/2019
    Primary completion :
    01/31/2023
    Completion :
    02/28/2024
    STAT3
    |
    tinengotinib (TT-00420)
    To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors (NCT05253053)
    Phase 1/2
    TransThera Sciences (Nanjing), Inc.
    Recruiting
    Last update posted :
    01/03/2024
    Initiation :
    04/13/2022
    Primary completion :
    09/01/2024
    Completion :
    12/01/2024
    HER-2 • FGFR2
    |
    PD-L1 expression • HER-2 negative
    |
    Tecentriq (atezolizumab) • albumin-bound paclitaxel • tinengotinib (TT-00420)
    Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor (NCT06057571)
    Phase 2
    TransThera Sciences (Nanjing), Inc.
    Recruiting
    Last update posted :
    01/01/2024
    Initiation :
    11/17/2023
    Primary completion :
    06/15/2025
    Completion :
    10/31/2025
    FGFR2
    |
    tinengotinib (TT-00420)